Zogenix, Inc (ZGNX) has announced that the U.S. Food and Drug Administration (FDA) has finally approved Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.The drug will now be launched through a restricted distribution program, and is expected to be available through Zogenix’s specialty pharmacy partner by the end of July.“The approval of Fintepla by the FDA is a significant milestone” cheered Stephen Farr, CEO of Zogenix. “We began this global development program nearly six years ago after researchers in Belgium recognized the potential of fenfluramine, a …read more
Source:: Yahoo Finance
